.@Novartis#India Can you explain how the prices of medicines had increased by 30% ? Manuf month and export month are same and in spite of it, difference in prices are more than 30% @PMOIndia@MoHFW_INDIA
Re the Novartis news today about data manipulation involving the world's most expensive drug: data manipulation in the drug industry is not new. This doesn't justify Novartis and it's concerning that this goes on.
All. The. Time.
https://t.co/dh8JsWKQ1g
A new study finds that nearly all patient charity programs run by the six largest organizations failed to provide assistance to people without insurance and were also more likely to cover expensive brand-name medicines over generics. https://t.co/gsNiMz3a3n
Some generic drugs aren't really generics at all. They're called authorized generics, but they're made by the brand name manufacturers to eat into the true generics' market share. Check out our latest @KHNews story: https://t.co/JPy1DXpPf1
The FDA can't keep up with the bad actors among the cheap foreign pharmaceuticals that now make up a huge chunk of the US generic market. More from @CharlesFLehman on @KatherineEban book tonight https://t.co/Cpz3MD72Oz
@forefrontindia@PMOIndia@WHO@CDSCO_INDIA_INF I suggest govt to form a doctors board to allow and carry out clinical trials in an ethical way. This illegal practice is happening because of regulatory rules. It should be abolished and trials of foreign firms should be considered as final to launch the similar drug here.
Dr. Reddy’s should be applauded for being able to duplicate mistakes at 2 different plants. Total mockery of FDA. Time to withdraw ANDA. Time fir FDA to act and not sleep. Another day, another Form 483 for a Dr. Reddy's plant | FiercePharma https://t.co/pBYHwmhx0m